Compare H2O America (HTO) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Summit Therapeutics Inc — how do they compare? H2O America trades at $63.79 (market cap $2.70B), while Summit Therapeutics Inc trades at $14.58 (market cap $10.48B). The key difference: Summit Therapeutics Inc is far larger — about 3.9× H2O America's market cap, and H2O America pays a 2.73% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HTO | SMMT | |
|---|---|---|
Market Cap | $2.70B | $10.48B |
Sector | Technology | Health |
52-Week High | $65.43 | $29.32 |
52-Week Low | $44.44 | $13.05 |
Enterprise Value | $4.42B | $9.90B |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $64.52, down 1.39% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported a Q1 2026 EPS beat of $0.50 versus $0.48 expected, with revenue of $816 million in 2026 and a net income margin of 12.86%. A dividend of $0.44 per share is scheduled for payment on June 1, 2026. Analyst consensus is strongly bullish with an 80% buy rating and a $63.50 price target.
The outlook for HTO is positive, supported by steady earnings growth, a reliable dividend, and strong institutional interest. Risks include high capital expenditure demands and sensitivity to regulatory changes in the utilities sector. The stock presents a value opportunity with a P/E of 22.11, trading near analyst targets with potential upside to the high target of $67.00.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
